Edivoxetine
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H26FNO4 |
Molar mass | 339.407 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Edivoxetine (INN; code name LY-2216684) is a drug which acts as a selective norepinephrine reuptake inhibitor and was under development by Eli Lilly for attention-deficit disorder (ADD) and as an antidepressant treatment.[1][2] It was in phase III clinical trials, in 2012, for major depressive disorder, but failed to get approval.[1][3]
Effectiveness
In a study published in 2010, edivoxetine succeeded to prove superiority over placebo, as measured by Hamilton Depression Rating Scale. However, effectiveness could be observed using the Self-Rated Quick Inventory of Depressive Symptomatology.[4]
In a study published in 2011, using the Montgomery–Åsberg Depression Rating Scale and the Sheehan Disability Scale, edivoxetine showed superiority over placebo, with higher response and remission rates.[5]
In December 2013, Eli Lilly announced that the clinical development of edivoxetine will be stopped due to lack of efficacy compared to SSRI alone in three separate clinical trials.[6]
Side effects
Side effects significantly associated with edivoxetine are headache, nausea, constipation, dry mouth and insomnia.[4]
The above-mentioned studies report increases of the cardiac rhythm, and one also increases of diastolic and systolic blood pressures.[4][5]
See also
References
- 1 2 Jun Yan (March 2012). "Pipeline for new antidepressants flowing slowly". Psychiatric News. American Psychiatric Association. 47 (5): 1b–29. doi:10.1176/pn.47.5.psychnews_47_5_1-b. Retrieved 2012-04-27.
- ↑ "Statement on a nonproprietary name adopted by the USAN council - Edivoxetine" (PDF) (Press release). American Medical Association. 2012. Retrieved 2012-04-12.
- ↑ Chancellor D (November 2011). "The depression market". Nature Reviews. Drug Discovery. 10 (11): 809–10. doi:10.1038/nrd3585. PMID 22037032. S2CID 3194093.
- 1 2 3 Dubé S, Dellva MA, Jones M, Kielbasa W, Padich R, Saha A, Rao P (April 2010). "A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression". Journal of Psychiatric Research. 44 (6): 356–363. doi:10.1016/j.jpsychires.2009.09.013. PMID 19909980.
- 1 2 Pangallo P, Dellva MA, D'Souza DN, Essink B, Russell J, Goldberger C (June 2011). "A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder". Journal of Psychiatric Research. 45 (6): 748–755. doi:10.1016/j.jpsychires.2011.03.014. PMID 21511276.
- ↑ "Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder | Eli Lilly and Company".